CGRP dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
CGRP is a peptide your body makes. It is one of the best-proven drug targets for migraine: four approved antibody shots and a group of pills called gepants all work by blocking it. When researchers gave CGRP itself to 13 migraine patients, 10 got a migraine-like attack. Nobody did on a dummy drip.
Evidence grade for CGRP: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 968 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 968
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 968 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Injury, healing and recovery, Bone and joints
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
CGRP is a peptide your own body makes. Nerves in the face and head release it, and it helps set off migraine. Good migraine drugs work by blocking it. Nobody takes CGRP itself.
What people take it for
- People look it up because of the migraine shots and pills that block it.
- Some mix up the peptide with the drugs and think the peptide is a treatment.
What studies in people showed
Blocking CGRP works. In a study of 955 people with migraine, a monthly shot that blocks it cut migraine days. People started at 8.3 days a month. They lost 3.2 or 3.7 days, depending on the dose. People on a dummy shot lost 1.8. Giving CGRP does the reverse. When 13 migraine patients got a CGRP drip, 10 had a migraine-like attack. None did on a dummy drip.
What people report
Reports, not study results
The good
- The drugs that block it cut migraine days in a large study, with side effects close to the dummy shot.
The bad
- Given as a drip, CGRP itself set off migraine-like attacks in 10 of 13 patients.
Where these come from: Both lines come from the studies on this page. We have not collected user reports on this one, since nobody sells CGRP as a supplement.
My bottom line
Do not take this. It gives migraine-prone people migraines. If migraines run your life, ask a doctor about the drugs that block it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals CGRP has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Pain968 people · 2 studies
35 of the 36 indexed goals have no study of any kind behind CGRP
No study in people, animals or cells on this page reports a result for these. That does not prove CGRP does nothing for them. It does mean anything you have heard about CGRP and one of these did not come from a study cited here.
Show full evidence
What is CGRP?
CGRP is a peptide your body makes. It is one of the best-proven drug targets for migraine: four approved antibody shots and a group of pills called gepants all work by blocking it. When researchers gave CGRP itself to 13 migraine patients, 10 got a migraine-like attack. Nobody did on a dummy drip.
CGRP is on this site for the opposite of the usual reason. Nobody should think about taking it. It is the body's own signal that, once blocked, gave us one of the real drug successes of the last ten years. It is a clean example of the gap between a drug target and a treatment.
It is a 37-building-block nerve peptide made from the CALCA gene. It is one of the strongest blood vessel wideners known. A second version, beta-CGRP, has its own page.
The approved drugs in this area all block it. The antibody shots are erenumab, which blocks the CGRP receptor, and fremanezumab, galcanezumab and eptinezumab, which grab the peptide itself. The pills that block the receptor are called gepants. They include ubrogepant, rimegepant, atogepant and zavegepant, used to stop an attack, prevent attacks, or both. These are prescription medicines backed by large studies.
The evidence for blocking it is strong. In the large STRIVE study, 955 people with migraine got a monthly shot of erenumab 70 mg, 140 mg or a dummy shot for six months. They started at 8.3 migraine days a month. Those days fell by 3.2 and 3.7 on the two doses, against 1.8 on the dummy. 43.3% and 50.0% of people cut their migraine days by at least half, against 26.6% on the dummy.
That evidence belongs to those drugs, and to blocking CGRP. It does not carry over to the peptide. When CGRP itself was dripped into 13 migraine patients, with a dummy drip on another day and nobody told which was which, 10 got a migraine-like attack. None did on the dummy. The typical worst headache scored 5 on CGRP and 2 on the dummy.
Nothing in the published research uses CGRP as a treatment for anything.
How does CGRP work?
Proven, and proven from both ends, which is rare. CGRP is released by the nerve that carries pain from the face and head. It acts on a two-part receptor, widens blood vessels and carries pain signals tied to migraine. Give it to people and it sets off migraine attacks. Block it, with an antibody against the peptide or its receptor or with a receptor-blocking pill, and attacks are prevented or stopped. Few targets in brain medicine have been proven from both ends in human experiments.
What have studies in people found about CGRP?
Lots of evidence, running two ways, and neither way supports taking CGRP. Blocking it prevents migraine in large studies. Giving it sets off migraine in controlled tests.
- Erenumab STRIVE study, 955 people: from 8.3 migraine days a month, days fell 3.2 on 70 mg and 3.7 on 140 mg, against 1.8 on a dummy shot. 43.3% and 50.0% halved their migraine days, against 26.6% on the dummy.
- CGRP given to 13 migraine patients, with a dummy drip on another day and nobody told which: 10 of 13 got a migraine-like attack on CGRP, none on the dummy. The typical worst headache scored 5 against 2.
- Four antibody shots that block CGRP are approved: erenumab, fremanezumab, galcanezumab and eptinezumab. Several gepant pills are approved: ubrogepant, rimegepant, atogepant and zavegepant.
- No study has given CGRP as a treatment for anything. No study has tested thinking with CGRP.
What this does not tell you: The human evidence here is about drugs that block CGRP. It tells you nothing about what taking CGRP would do, except through the tests where it was given on purpose. Those tell you it would probably give a migraine-prone person a migraine. Reading the strength of the blocker evidence as support for the peptide is exactly the mistake this page exists to prevent.
The state of the research
CGRP is a signal your body makes, not a research chemical and not a product. Stamping 'not approved, research use only' on something your body makes all day would tell readers something false. That is why this page files it as a natural body signal and names the approved drugs.
This page guards against a common trick in peptide marketing. A peptide has a big, impressive pile of studies, and those studies are about a drug that blocks it. Reading the study count as a vote for the peptide gets the direction exactly backwards. Here the flip is unusually clear. The same research field that made the antibodies also ran the tests of giving CGRP, so both directions were measured in people.
The practical point is short. Nobody sells CGRP as a supplement, and nobody should. If you are interested in the migraine drugs, they are erenumab, fremanezumab, galcanezumab, eptinezumab and the gepants. They are prescription medicines backed by large final-stage studies.
A real test of thinking means a proper test of memory, attention, speed or planning. You take it before and after, and you are compared with a group who got a dummy and did not know it. None of the seven compounds in this group has ever been tested that way. Scores for tiredness, anxiety, hunger or a doctor's overall impression are not thinking tests. Neither is a hormone level. This matters because several of these compounds are sold for focus, clarity and mental energy, and the studies behind them measured none of those things.
The evidence, in charts
Fig. 1a · how many people
968people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| The New England Journal of Medicine 2017 | 955 | 99% |
| The Journal of Headache and Pain 2018 | 13 | 1% |
One study holds 99% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 4 sources here are studies in people. The rest are not.
- Study in people · done in people250%
- Review of studies · sums up other studies250%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2017 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- A 37 residue peptide, roughly 3.8 kDa.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- 37 amino acidscounted from the chain below
Half-life as stated on file: Short in circulation, consistent with its role as a locally released neuropeptide rather than a circulating hormone. No specific figure is asserted here because none was resolved in this pass. The antibodies that block it are dosed monthly or quarterly, and that long duration is a property of the antibodies, not of CGRP.
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF
- Water-shy 19
- Water-loving 12
- Acidic 1
- Basic 5
One square per amino acid, left to right from the start of the chain, coloured by type. The type is a fact about the amino acid, not a finding about this compound.
The studies we cite
- Study in people2018Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
Give a person this peptide and it gives them a migraine. Thirteen migraine patients each got CGRP on one day and a dummy infusion on another, without being told which was which. Ten of the thirteen developed a migraine-like attack on CGRP. Nobody did on the dummy. The headaches were worse and they lasted longer. That is why this peptide is something drug companies try to block, not something to take. The senior author advises several of those companies, which he declares.
What happens when you give CGRP to a human. Thirteen migraine patients previously enrolled in erenumab trials received CGRP in a double-blind, placebo-controlled, randomised crossover design. CGRP induced migraine-like attacks in 10 of 13 patients (77%) compared with none after placebo, P = 0.002. Area under the curve for headache intensity was greater after CGRP at 0 to 90 minutes (P = 0.009) and 2 to 12 hours (P = 0.014), and median peak headache intensity was 5 against 2 on placebo (P = 0.004). Registered NCT03481400. The senior author discloses consultancy or advisory relationships with Allergan, Amgen, Alder, Eli Lilly, Novartis and Teva.
- Study in people2017A Controlled Trial of Erenumab for Episodic Migraine
The money in this peptide is in blocking it, and blocking it clearly works. 955 people with migraine got a monthly shot of one of two erenumab doses, or a dummy shot, for six months. They started with roughly eight migraine days a month. On the drug they lost between three and four of those days. On the dummy they lost under two. Half the people on the higher dose cut their migraine days by at least half. Side effects matched the dummy. Several authors work for the maker.
The scale of evidence behind blocking this peptide, not administering it. 955 patients randomised to subcutaneous erenumab 70 mg (n=317), 140 mg (n=319) or placebo (n=319) monthly for six months. From a baseline of 8.3 monthly migraine days, days fell by 3.2 and 3.7 respectively against 1.8 on placebo (P<0.001 for each dose). A 50% or greater reduction was reached by 43.3% and 50.0% against 26.6% on placebo. Adverse event rates were similar to placebo. Several authors are Amgen employees.
- Review of studies2025Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
A 2025 review of the drugs that block CGRP: the antibody shots and the gepant pills. Useful as a map of which approved drugs act here and how. It covers blocking CGRP, not giving it.
A 2025 review of the CGRP-targeted drug class, describing the current clinical role of the monoclonal antibodies and gepants. Useful as the map of which approved molecules act on this pathway and how. It reviews blockade of CGRP; it does not describe any therapeutic use of CGRP itself.
- Review of studies2020Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
A review of what CGRP does in migraine and why blocking it makes sense. It treats CGRP as a target to block, not a treatment to take.
A review of the peptide's role in migraine pathophysiology and of the logic of targeting it. Establishes the framing that CGRP is a validated target rather than a candidate treatment.
Where to buy CGRP
No seller we track lists CGRP yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has CGRP been tested in people?
Yes. 968 people given it across 2 completed trials cited here, 0 of which found nothing. CGRP is a peptide your body makes. It is one of the best-proven drug targets for migraine: four approved antibody shots and a group of pills called gepants all work by blocking it. When researchers gave CGRP itself to 13 migraine patients, 10 got a migraine-like attack. Nobody did on a dummy drip.
What is the CGRP dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 968 people given it
Is CGRP FDA-approved?
CGRP is a peptide the body makes. It is not a medicine, so it has no FDA status. Several drugs aimed at it are FDA-approved. Some are lab-made antibodies: erenumab, fremanezumab, galcanezumab and eptinezumab. Others are pills called gepants, including ubrogepant, rimegepant, atogepant and zavegepant. Those approvals belong to those drugs, and they all block CGRP. None of them gives you CGRP.
Can I take CGRP?
No, and you would not want to. When CGRP was dripped into 13 migraine patients, with a dummy drip on another day and nobody told which, 10 got a migraine-like attack. None did on the dummy. CGRP is something good drugs block, not a treatment.
What drugs target CGRP?
Four approved antibody shots: erenumab, which blocks the CGRP receptor, and fremanezumab, galcanezumab and eptinezumab, which grab the peptide itself. Plus the receptor-blocking pills called gepants, including ubrogepant, rimegepant, atogepant and zavegepant. They are used to stop attacks, prevent them, or both.
Is CGRP a research chemical?
No. It is a peptide your own body makes. It is released by the nerve that carries pain from the face and head, made from the CALCA gene, and 37 building blocks long. It is not a product, has no approval status of its own, and is not sold as a supplement.
How well do the CGRP blockers work?
In the large erenumab study of 955 people with migraine, monthly migraine days fell by 3.2 on 70 mg and 3.7 on 140 mg, against 1.8 on a dummy shot. They started at 8.3 days. Half the people on 140 mg cut their migraine days by at least half, against about a quarter on the dummy. That is a real effect. But a quarter of people on the dummy also halved their migraine days, which is why the dummy group matters.
Does CGRP have anything to do with cognition or nootropics?
No controlled study has made thinking its main measure, with CGRP or with the drugs that block it. Studies here measure migraine days, how bad the headache is, and how often people need rescue pills.